Posterior Reversible Encephalopathy Syndrome and Anti-Angiogenic Agents: A Case Report

Silva, Filipe Manuel Dos Reis Simões da; Pêgo, P; Vendrell, Maria Cristina Henriques; Farias, Maria João de Azevedo Batalha Ferreira Dos Santos; Timóteo, Ângela; Costa, Márcia Gisele Santos da; Cravo, Isabel; Gomes, Francisco Carrasquinho

doi:10.3109/01658107.2010.539763

Cited by 11 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, one patient receiving sunitinib who developed PRES with concomitant hypertension experienced clinical improvement 3 days after the introduction of antihypertensive drugs, whereas sunitinib was stopped only on day 4 [18]. This case suggests that blood pressure control is critical for the management of PRES, whereas the discontinuation of the anti-VEGF per se might not be sufficient to improve the neurological status.…”

Section: Discussionmentioning

confidence: 70%

Posterior reversible encephalopathy syndrome induced by anti-VEGF agents

et al. 2011

View full text Add to dashboard Cite

Posterior reversible encephalopathy syndrome (PRES) is a clinico-radiological entity that may occur in patients receiving anti-vascular endothelial growth factor (VEGF) agents such as bevacizumab and tyrosine kinase inhibitors. Little is known about the characteristics of patients at risk for PRES under anti-VEGF agents. We carried out a comprehensive review of reports documenting the occurrence of PRES in patients receiving anti-VEGF agents. Twenty-six patients are described with a majority of females (73.1%). Almost a third of patients had a past history of hypertension. The most common symptoms included headache, visual disturbance and seizure. A vast majority of patients had hypertension at the diagnosis of PRES, and proteinuria was detectable each time it was investigated. Neurological outcome was favorable in all cases with a symptomatic treatment including blood pressure control. The risk of PRES is increased when blood pressure is poorly controlled and when proteinuria is detectable. The clinical course appears favorable with a symptomatic treatment. PRES is a potentially severe but manageable toxicity of anti-VEGF agents.

show abstract

Section: Discussionmentioning

confidence: 70%

Posterior reversible encephalopathy syndrome induced by anti-VEGF agents

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Although there have been 2 reports (1,2) documenting complex visual hallucinations following presumed PRES, this report documents the first case of definitive CBS following PRES.…”

mentioning

confidence: 72%

“…A second report out of Portugal in 2011 documented PRES in a man who presented initially with simple visual hallucinations that were followed by vision loss reduced to no light perception (2). After his visual improvement, up to 6/10, his hallucinations actually worsened and became complex, and were not labelled as CBS.…”

mentioning

confidence: 99%

Recovery From Charles Bonnet Syndrome Following Posterior Reversible Encephalopathy Syndrome

Huang

Jiang²,

Khan³

et al. 2021

Journal of Neuro-Ophthalmology

View full text Add to dashboard Cite

“…PRES is characterized by seizure, headache, impaired vision, and hypertension. A relationship between PRES and cancer medications including cytotoxic chemotherapeutics and newer agents that target VEGF such as bevacizumab, sunitinib, and pazopanib has been observed [ 27 , 28 ]. Case reports suggest visual disturbance symptoms 10 week to 4 months after systemic therapy initiation with these agents.…”

Section: Discussionmentioning

confidence: 99%

Ocular complications with the use of radium-223: a case series

et al. 2022

View full text Add to dashboard Cite

Background Radium-223 is used for the treatment of osseous metastases in castrate-resistant prostate cancer, and has been shown to increase time to the first skeletal-related event, reduce the rate of hospitalization, and improve quality of life. It is well tolerated, with hematologic toxicity as the main adverse event. Thus far, no ocular complication has been reported in the literature after initial administration of radium-223 with a single case reported of ocular complications after a patient’s second course of radium-223. Case presentations We present three cases of ocular complications after the use of radium-223 in patients with metastatic prostatic adenocarcinoma. Ocular complications presented as blurry vision, and formal diagnosis included uveitis and hyphema. Conclusions Documentation of adverse events is exceedingly important due to the high incidence of metastatic prostate cancer and increasing interest for the use of radium-223 in other osteoblastic disease. The authors postulate that these ocular complications may be a result of radiation’s potential effect on neovascularization, polypharmacy, or the biomolecular effects of radium-223 on integral signaling proteins, potentially coupled with poor underlying ocular health.

show abstract

Posterior Reversible Encephalopathy Syndrome and Anti-Angiogenic Agents: A Case Report

Cited by 11 publications

References 32 publications

Posterior reversible encephalopathy syndrome induced by anti-VEGF agents

Posterior reversible encephalopathy syndrome induced by anti-VEGF agents

Recovery From Charles Bonnet Syndrome Following Posterior Reversible Encephalopathy Syndrome

Ocular complications with the use of radium-223: a case series

Contact Info

Product

Resources

About